These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 1320634)
1. Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma. Lehtinen M; Leminen A; Paavonen J; Lehtovirta P; Hyöty H; Vesterinen E; Dillner J J Clin Pathol; 1992 Jun; 45(6):494-7. PubMed ID: 1320634 [TBL] [Abstract][Full Text] [Related]
2. Pre- and posttreatment serum antibody responses to HPV 16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma. Lehtinen M; Leminen A; Kuoppala T; Tiikkainen M; Lehtinen T; Lehtovirta P; Punnonen R; Vesterinen E; Paavonen J J Med Virol; 1992 Jul; 37(3):180-6. PubMed ID: 1331306 [TBL] [Abstract][Full Text] [Related]
3. A population-based seroepidemiological study of cervical cancer. Dillner J; Lenner P; Lehtinen M; Eklund C; Heino P; Wiklund F; Hallmans G; Stendahl U Cancer Res; 1994 Jan; 54(1):134-41. PubMed ID: 8261434 [TBL] [Abstract][Full Text] [Related]
4. Seric and local antibodies against a synthetic peptide of HPV16. Dreyfus M; Baldauf JJ; Ritter J; Obert G Eur J Obstet Gynecol Reprod Biol; 1995 Apr; 59(2):187-91. PubMed ID: 7657014 [TBL] [Abstract][Full Text] [Related]
5. Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Rocha-Zavaleta L; Jordan D; Pepper S; Corbitt G; Clarke F; Maitland NJ; Sanders CM; Arrand JR; Stern PL; Stacey SN Br J Cancer; 1997; 75(8):1144-50. PubMed ID: 9099962 [TBL] [Abstract][Full Text] [Related]
6. Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Mann VM; de Lao SL; Brenes M; Brinton LA; Rawls JA; Green M; Reeves WC; Rawls WE Cancer Res; 1990 Dec; 50(24):7815-9. PubMed ID: 2174733 [TBL] [Abstract][Full Text] [Related]
7. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Dillner L; Zellbi A; Avall-Lundqvist E; Heino P; Eklund C; Pettersson CA; Forslund O; Hansson BG; Grandien M; Bistoletti P Cancer Detect Prev; 1995; 19(5):381-93. PubMed ID: 7585724 [TBL] [Abstract][Full Text] [Related]
8. Presence of antibody reactive with synthetic peptide derived from L2 open reading frame of human papillomavirus types 6b and 11 in human sera. Suchánková A; Ritter O; Hirsch I; Krchnák V; Kalos Z; Hamsíková E; Brichácek B; Vonka V Acta Virol; 1990 Sep; 34(5):433-42. PubMed ID: 1705748 [TBL] [Abstract][Full Text] [Related]
9. A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. Strickler HD; Dillner J; Schiffman MH; Eklund C; Glass AG; Greer C; Scott DR; Sherman ME; Kurman RJ; Manos M Viral Immunol; 1994; 7(4):169-77. PubMed ID: 7576031 [TBL] [Abstract][Full Text] [Related]
10. Use of antibodies against a synthetic peptide of the E6 protein of human papillomavirus (HPV) type 16 for the diagnosis of genital HPV lesions. Tosi P; Pallini V; Cintorino M; Bugnoli M; Covacci A; Petracca R; Syrjänen S; Del Vecchio MT; Mäntyjärvi R; Ruggiero P Cytopathology; 1993; 4(1):3-15. PubMed ID: 8384016 [TBL] [Abstract][Full Text] [Related]
11. Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma. Heino P; Goldman S; Lagerstedt U; Dillner J Int J Cancer; 1993 Feb; 53(3):377-81. PubMed ID: 8381393 [TBL] [Abstract][Full Text] [Related]
13. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. Petter A; Heim K; Guger M; Ciresa-Kö Nig A; Christensen N; Sarcletti M; Wieland U; Pfister H; Zangerle R; Höpfl R J Gen Virol; 2000 Mar; 81(Pt 3):701-8. PubMed ID: 10675407 [TBL] [Abstract][Full Text] [Related]
14. Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia. Dillner L; Bekassy Z; Jonsson N; Moreno-Lopez J; Blomberg J Int J Cancer; 1989 Jan; 43(1):36-40. PubMed ID: 2536005 [TBL] [Abstract][Full Text] [Related]
15. Serological evidence for the association of papillomavirus and cervical neoplasia. Baird PJ Lancet; 1983 Jul; 2(8340):17-8. PubMed ID: 6134887 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia. Sharma BK; Ray A; Murthy NS Eur J Cancer; 1996 May; 32A(5):872-6. PubMed ID: 9081369 [TBL] [Abstract][Full Text] [Related]
17. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions. Marais DJ; Vardas E; Ramjee G; Allan B; Kay P; Rose RC; Williamson AL J Infect Dis; 2000 Oct; 182(4):1239-42. PubMed ID: 10979925 [TBL] [Abstract][Full Text] [Related]
18. Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer. Kanda T; Onda T; Zanma S; Yasugi T; Furuno A; Watanabe S; Kawana T; Sugase M; Ueda K; Sonoda T Virology; 1992 Oct; 190(2):724-32. PubMed ID: 1325704 [TBL] [Abstract][Full Text] [Related]
19. Serological responses to human papillomavirus type 16 antigens in women before and after renal transplantation. Lewensohn-Fuchs I; Wester D; Bistoletti P; Elfgren K; Ohlman S; Dillner J; Dalianis T J Med Virol; 1993 Jul; 40(3):188-92. PubMed ID: 8394870 [TBL] [Abstract][Full Text] [Related]
20. Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Dillner J; Dillner L; Utter G; Eklund C; Rotola A; Costa S; DiLuca D Int J Cancer; 1990 Mar; 45(3):529-35. PubMed ID: 1689705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]